Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

Canaccord Genuity analyst William Maughan maintained a Buy rating and increased the price target from $171 to $171.44 on Nov. 27, 2024. This analyst has an accuracy rate of 71%. JP Morgan analyst ...

Lehigh County Courthouse staffer Adam Young sits with his face shield on as a juror would during a video shoot at the ...

A CJEU copyright decision on employees' rights and an update on an IP feud concerning foreign rights over 'Superman' were ...

SVB Wealth LLC bought a new stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) in the fourth quarter, Holdings ...

Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seventeen analysts that are covering the firm, Marketbeat Ratings reports. Three ...

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...

In a report released yesterday, Harry Gillis from Berenberg Bank maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and more.

A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make ...